MPN Research Foundation is proud to celebrate the 10-year anniversary of the identification of CALR as a common driver of MPNs. We funded early work that discovered this MPN driver mutation. Learn more >
invested in research
supported research
What is
essential
thrombocythemia
(ET)?
Essential Thrombocythemia (ET)
Most commonly diagnosed in women over the age of 50, ET is associated with a proliferation of platelet precursors in the bone marrow and complications frequently include blood clotting and/or bleeding.
Learn more about ETWhat is
polycythemia vera
(PV)?
Polycythemia vera (PV)
The disease is most common in men over the age of 60, but anyone can develop PV. PV patients typically experience an elevated red blood cell count, an elevated platelet count and an enlarged spleen, especially over time.
Learn more about PVWhat is
myelofibrosis
(MF)?
Myelofibrosis (MF)
MF is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells.
Learn more about MFPatients, clinicians, researchers, and the biotech and pharma industries all have critical roles to play in advancing MPN research and are all important members of the MPNRF community.
Connect with us to be part of our coordinated effort to find new treatments — and eventually cures — for MPNs.
Patients
and
Caregivers
Every patient experience is unique and provides new clues for researchers and clinicians.
Researchers
and
Clinicians
In our 24-year history, MPNRF has contributed to some of the most influential MPN research discoveries.
Industry
and
Biopharma
Engage with us to ensure that new therapies have the maximum impact on patient outcomes and quality of life.
Download our Voice of the Patient report
Ready to do more?
Julie and her family joined team MPN and created HikeMF to join the fight against MPNs.
Stay connected
Invest in MPN research
Your investment supports doctors and researchers around the world who are dedicated to finding cures for MPNs.